benzofurazan-4-carboxylic acid | 32863-21-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶二唑类
• 英文名称: benzofurazan-4-carboxylic acid
• 英文别名: 4-Carboxy-benzo-2,1,3-oxadiazol；benzo[1,2,5]oxadiazole-4-carboxylic acid；Benzo[c][1,2,5]oxadiazole-4-carboxylic acid；2,1,3-benzoxadiazole-4-carboxylic acid
• CAS: 32863-21-1
• 化学式: C₇H₄N₂O₃
• 分子量: 164.12
• InChiKey: NGPYWZBQSYAKKK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  76.2
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  benzofurazan-4-carboxylic acid 在 氯化亚砜 、 N,N-二甲基甲酰胺 作用下， 反应 0.5h， 生成 benzofurazan-4-carboxylic acid methyl ester
  参考文献：
  名称：

  Nitroanilines are the reduction products of benzofuroxan system by oxyhemoglobin (HbO22+)

  摘要：

  Benzofuroxans are interesting compounds which display several biochemical and pharmacological properties. Recent studies from our laboratory demonstrate that they are reduced by ferrous salts at room temperature and that the principal reaction products are o-nitroanilines. This paper shows that simple benzofuroxan derivatives are also able to oxidise HbO(2)(2+) to methemoglobin (MetHb(3+)) (UV detection) and to form o-nitroanilines (HPLC detection). From a toxicological point of view this reaction is interesting, since it indicates that the blood is a site for metabolism of these compounds with consequent methemoglobinemia and formation of toxic compounds. (C) 2001 Elsevier Science S.A. All rights reserved.

  DOI：

  10.1016/s0014-827x(01)01139-9
• 作为产物：
  描述：

  苯并二唑-4-甲醛 在 sodium hydroxide 作用下， 以 四氢呋喃 为溶剂， 反应 10.0h， 以57%的产率得到benzofurazan-4-carboxylic acid
  参考文献：
  名称：

  一种伊拉地平杂质Ⅱ的制备方法

  摘要：

  本发明公开了一种伊拉地平杂质Ⅱ的制备方法，其特征在于：以苯并噁二唑‑4‑甲醛为原料，在碱性有机条件下发生歧化反应，经分离得到伊拉地平杂质Ⅱ，反应式如下：该伊拉地平杂质Ⅱ制备工艺简单，原料易得，所得产品纯度高(HPLC≥99％)，可直接用于伊拉地平关键中间体(化合物2)的质量研究。

  公开号：

  CN106967006A

文献信息

• THIAZOLIDINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS
  申请人：Aissaoui Hamed

  公开号：US20100113531A1

  公开（公告）日：2010-05-06

  The invention relates to novel thiazolidine derivatives of the formula (I) wherein A and R 1 are as described in the description and their use as medicaments, especially as orexin receptor antagonists.

  本发明涉及式(I)的新噻唑啉衍生物，其中A和R1如描述中所述，以及它们作为药物的使用，尤其是作为食欲素受体拮抗剂的使用。
• [EN] THIAZOLIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS<br/>[FR] COMPOSÉS THIAZOLIDINES EN TANT QU'ANTAGONISTES DES RÉCEPTEURS DE L'OREXINE
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2010004507A1

  公开（公告）日：2010-01-14

  The invention relates to thiazolidine derivatives of the formula (I) wherein A, B, and R1 are as described in the description, to salts, especially pharmaceutically acceptable salts, of such compounds and to their use as medicaments, especially as orexin receptor antagonists.

  这项发明涉及式(I)的噻唑啉衍生物，其中A、B和R1如描述中所述，以及这些化合物的盐，特别是药学上可接受的盐，以及它们作为药物的用途，特别是作为促进睡眠的药物受体拮抗剂。
• THIAZOLIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS
  申请人：Aissaoui Hamed

  公开号：US20110105491A1

  公开（公告）日：2011-05-05

  The invention relates to thiazolidine derivatives of the formula (I) wherein A, B, and R 1 are as described in the description, to salts, especially pharmaceutically acceptable salts, of such compounds and to their use as medicaments, especially as orexin receptor antagonists.

  这项发明涉及式(I)的噻唑啉衍生物，其中A、B和R1如描述中所述，以及这些化合物的盐，特别是药用可接受的盐，以及它们作为药物的用途，特别是作为促进睡眠的药物受体拮抗剂。
• Ccr5 antagonists as therapeutic agents
  申请人：Kazmierski Mieczyslaw Wieslaw

  公开号：US20060229336A1

  公开（公告）日：2006-10-12

  The present invention relates to compounds of formula (I) or a pharmaceutically acceptable derivatives thereof, useful in the treatment of prophylazis of CCR5-related diseases and disorders, for example, in the inhibition of HIV replication, the prevention or treatment of HIV infection, and in the treatment of the resulting acquired immune deficiency syndrome (AIDS).

  本发明涉及式(I)化合物或其药学上可接受的衍生物，用于预防CCR5相关疾病和障碍的治疗，例如，抑制HIV复制，预防或治疗HIV感染，以及治疗由此产生的获得性免疫缺陷综合症（AIDS）。
• DI-SUBSTITUTED AMIDES FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES
  申请人：Street Leslie

  公开号：US20120035173A1

  公开（公告）日：2012-02-09

  This invention relates to compounds, pharmaceutical compositions and methods for use in the prevention and treatment of cerebral insufficiency, including enhancement of receptor functioning in synapses in brain networks responsible for basic and higher order behaviors. These brain networks, which are involved in regulation of breathing, and cognitive abilities related to memory impairment, such as is observed in a variety of dementias, in imbalances in neuronal activity between different brain regions, as is suggested in disorders such as Parkinson's disease, schizophrenia, respiratory depression, sleep apneas, attention deficit hyperactivity disorder and affective or mood disorders, among numerous others. In a particular aspect, the invention relates to compounds useful for treatment of such conditions, and methods of using these compounds for such treatment.

  本发明涉及化合物、药物组合物及其在预防和治疗脑供血不足方面的应用方法，包括增强与基本和高级行为有关的脑网络中突触中受体功能。这些脑网络涉及呼吸调节和与记忆障碍相关的认知能力，例如在各种痴呆症中观察到的情况，以及在不同脑区域之间的神经活动失衡中所建议的帕金森病、精神分裂症、呼吸抑制、睡眠呼吸暂停、注意力缺陷多动障碍和情感或心境障碍等多种疾病。在一个特定的方面，本发明涉及用于治疗此类疾病的化合物，以及使用这些化合物进行此类治疗的方法。